Perioperative Outcomes in Transcarotid Artery Revascularization Versus Carotid Endarterectomy or Stenting Nationwide

医学 颈动脉内膜切除术 优势比 冲程(发动机) 围手术期 颈动脉支架置入术 内科学 置信区间 血运重建 共病 心脏病学 动脉内膜切除术 颈动脉疾病 狭窄 心肌梗塞 外科 冠状动脉疾病 可能性 动脉 放射科 逻辑回归
作者
Ian Ramsay,Joshua D. Burks,Victor M. Lu,Michael Silva,Ahmed Abdelsalam,Robert M. Starke,Evan Luther
出处
期刊:Operative Neurosurgery [Lippincott Williams & Wilkins]
卷期号:25 (5): 453-460 被引量:4
标识
DOI:10.1227/ons.0000000000000865
摘要

BACKGROUND AND OBJECTIVES: Transcarotid artery revascularization (TCAR) is a newer treatment for carotid stenosis where the carotid artery is accessed directly in the neck for stenting. It is less invasive than carotid endarterectomy (CEA) and has less embolic potential than carotid artery stenting (CAS), but population-level utilization of TCAR and outcomes are currently unknown. Our study compares outcomes of TCAR with those of CEA and CAS. METHODS: The National Inpatient Database was used for years 2015 to 2019. A multivariate logistic regression model was used to compare CEA, CAS, and TCAR outcomes with age, sex, race, hospital teaching status, symptomatic carotid disease status, side of procedure, intraoperative monitoring, and the weighted Elixhauser comorbidity score as covariates. RESULTS: TCAR comprised 0.69% of these procedures in 2016, rising to 1.35% in 2019. The inpatient rates of death, stroke, and myocardial infarction for TCAR were 0.63% (95% confidence interval: 0.36%, 1.06%), 0.42% (0.21%, 0.80%), and 1.46% (1.04%, 2.05%), respectively. Compared with CEA, TCAR had statistically insignificant difference odds of death, odds ratio (95% CI) for stroke was 0.47 (0.25, 0.87), and for myocardial infarction, it was 0.66 (0.37, 0.94). Compared with CAS, for TCAR, the odds ratio for death was 0.41 (0.24, 0.71), and for stroke, it was 0.48 (0.26, 0.91). CONCLUSION: TCAR is underutilized relative to other revascularization techniques yet has favorable outcomes compared with CEA and CAS. TCAR may be preferred to CAS in patients not surgical candidates for CEA and has a less invasive possibility for those eligible for CEA.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Cecilia0_0完成签到,获得积分10
刚刚
又壮了发布了新的文献求助20
刚刚
友好的易槐完成签到,获得积分10
2秒前
青山发布了新的文献求助10
2秒前
飘逸凝丝发布了新的文献求助10
2秒前
2秒前
Yddear发布了新的文献求助20
2秒前
2秒前
poletar发布了新的文献求助10
3秒前
EWW发布了新的文献求助20
3秒前
xxw发布了新的文献求助10
3秒前
4秒前
4秒前
一休关注了科研通微信公众号
4秒前
Ivy完成签到,获得积分10
4秒前
5秒前
5秒前
Syyyyy发布了新的文献求助10
6秒前
6秒前
6秒前
华仔应助aa采纳,获得10
6秒前
魁梧的灵安关注了科研通微信公众号
6秒前
6秒前
7秒前
小龙发布了新的文献求助10
7秒前
TTT完成签到,获得积分10
7秒前
yinghua发布了新的文献求助10
7秒前
美好斓发布了新的文献求助10
7秒前
Lisuo应助飞宇采纳,获得20
8秒前
8秒前
鸟史发布了新的文献求助10
9秒前
哇哇哇哇发布了新的文献求助30
10秒前
Haoea发布了新的文献求助10
10秒前
胖头鱼发布了新的文献求助10
10秒前
小新完成签到 ,获得积分20
10秒前
Zx_1993应助念安采纳,获得20
10秒前
陶醉小笼包完成签到,获得积分10
11秒前
传奇3应助爱美丽采纳,获得10
11秒前
11秒前
吕嘉焓完成签到,获得积分10
11秒前
高分求助中
美国药典 2000
Fermented Coffee Market 2000
合成生物食品制造技术导则,团体标准,编号:T/CITS 396-2025 1000
The Leucovorin Guide for Parents: Understanding Autism’s Folate 1000
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
Critical Thinking: Tools for Taking Charge of Your Learning and Your Life 4th Edition 500
Comparing natural with chemical additive production 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5239828
求助须知:如何正确求助?哪些是违规求助? 4407067
关于积分的说明 13717174
捐赠科研通 4275655
什么是DOI,文献DOI怎么找? 2346104
邀请新用户注册赠送积分活动 1343227
关于科研通互助平台的介绍 1301291